At Exceedance 2020, RMS explored the key forces currently disrupting the industry, from technology, data analytics and the cloud through to rising extremes of catastrophic events like the pandemic and climate change. This coupling of technological and environmental disruption represents a true inflection point for the industry. EXPOSURE asked six experts across RMS for their views on why they believe these forces will change everything Cloud Computing: Moe Khosravy, Executive Vice President, Software and Platforms How are you seeing businesses transition their workloads over to the cloud? I have to say it’s been remarkable. We’re way past basic conversations on the value proposition of the cloud to now having deep technical discussions that are truly transformative plays. Customers are looking for solutions that seamlessly scale with their business and platforms that lower their cost of ownership while delivering capabilities that can be consumed from anywhere in the world. Why is the cloud so important or relevant now? It is now hard for a business to beat the benefits that the cloud offers and getting harder to justify buying and supporting complex in-house IT infrastructure. There is also a mindset shift going on — why is an in-house IT team responsible for running and supporting another vendor’s software on their systems if the vendor itself can provide that solution? This burden can now be lifted using the cloud, letting the business concentrate on what it does best. Has the pandemic affected views of being in the cloud? I would say absolutely. We have always emphasized the importance of cloud and true SaaS architectures to enable business continuity — allowing you to do your work from anywhere, decoupled from your IT and physical footprint. Never has the importance of this been more clearly underlined than during the past few months. Risk Analytics: Cihan Biyikoglu, Executive Vice President, Product What are the specific industry challenges that risk analytics is solving or has the potential to solve? Risk analytics really is a wide field, but in the immediate short term one of the focus areas for us is improving productivity around data. So much time is spent by businesses trying to manually process data — cleansing, completing and correcting data — and on conversion between incompatible datasets. This alone is a huge barrier just to get a single set of results. If we can take this burden away, give decision-makers the power to get results in real time with automated and efficient data handling, then with that I believe we will liberate them to use the latest insights to drive business results. Another important innovation here are the HD Models™. The power of the new engine with its improved accuracy I believe is a game changer that will give our customers a competitive edge. How will risk analytics impact activities and capabilities within the market? As seen in other industries, the more data you can combine, the better the analytics become — that’s the universal law of analytics. Getting all of this data on a unified platform and combining different datasets unearths new insights, which could produce opportunities to serve customers better and drive profit or growth. What are the longer-term implications for risk analytics? In my view, it’s about generating more effective risk insights from analytics, results in better decision- making and the ability to explore new product areas with more confidence. It will spark a wave of innovation to profitably serve customers with exciting products and understand the risk and cost drivers more clearly. How is RMS capitalizing on risk analytics? At RMS, we have the pieces in place for clients to accelerate their risk analytics with the unified, open platform, Risk Intelligence™, which is built on a Risk Data Lake™ in the cloud and is ready to take all sources of data and unearth new insights. Applications such as Risk Modeler™ and ExposureIQ™ can quickly get decision-makers to the analytics they need to influence their business. Open Standards: Dr. Paul Reed, Technical Program Manager, RDOS Why are open standards so important and relevant now? I think the challenges of risk data interoperability and supporting new lines of business have been recognized for many years, as companies have been forced to rework existing data standards to try to accommodate emerging risks and to squeeze more data into proprietary standards that can trace their origins to the 1990s. Today, however, with the availability of big data technology, cloud platforms such as RMS Risk Intelligence and standards such as the Risk Data Open Standard™ (RDOS) allow support for high-resolution risk modeling, new classes of risk, complex contract structures and simplified data exchange. Are there specific industry challenges that open standards are solving or have the potential to solve? I would say that open standards such as the RDOS are helping to solve risk data interoperability challenges, which have been hindering the industry, and provide support for new lines of business. In the case of the RDOS, it’s specifically designed for extensibility, to create a risk data exchange standard that is future-proof and can be readily modified and adapted to meet both current and future requirements. Open standards in other industries, such as Kubernetes, Hadoop and HTML, have proven to be catalysts for collaborative innovation, enabling accelerated development of new capabilities. How is RMS responding to and capitalizing on this development? RMS contributed the RDOS to the industry, and we are using it as the data framework for our platform called Risk Intelligence. The RDOS is free for anyone to use, and anyone can contribute updates that can expand the value and utility of the standard — so its development and direction is not dependent on a single vendor. We’ve put in place an independent steering committee to guide the development of the standard, currently made up of 15 companies. It provides benefits to RMS clients not only by enhancing the new RMS platform and applications, but also by enabling other industry users who create new and innovative products and address new and emerging risk classes. Pandemic Risk: Dr. Gordon Woo, Catastrophist How does pandemic risk affect the market? There’s no doubt that the current pandemic represents a globally systemic risk across many market sectors, and insurers are working out both what the impact from claims will be and the impact on capital. For very good reasons, people are categorizing the COVID-19 disease as a game-changer. However, in my view, SARS [severe acute respiratory syndrome] in 2003, MERS [Middle East respiratory syndrome] in 2012 and Ebola in 2014 should also have been game-changers. Over the last decade alone, we have seen multiple near misses. It’s likely that suppression strategies to combat the coronavirus will probably continue in some form until a vaccine is developed, and governments must strike this uneasy balance between their economies and the opening of their populations to exposure from the virus. What are the longer-term implications of this current pandemic for the industry? It’s clear that the mitigation of pandemic risk will need to be prioritized and given far more urgency than before. There’s no doubt in my mind that events such as the 2014 Ebola crisis were a missed opportunity for new initiatives in pandemic risk mitigation. Away from the life and health sector, all insurers will need to have a better grasp on future pandemics, after seeing the impact of COVID-19 and its wide business impact. The market could look to bold initiatives with governments to examine how to cover future pandemics, similar to how terror attacks are covered as a pooled risk. How is RMS helping its clients in relation to COVID-19? Since early January when the first cases emerged from Wuhan, China, we’ve been supporting our clients and the wider market in gaining a better understanding of the diverse loss implications of COVID-19. Our LifeRisks® team has been actively assisting in pandemic risk management, with regular communications and briefings, and will incorporate new perspectives from COVID-19 into our infectious diseases modeling. Climate Change: Ryan Ogaard, Senior Vice President, Model Product Management Why is climate change so relevant to the market now? There are many reasons. Insurers and their stakeholders are looking at the constant flow of catastrophes, from the U.S. hurricane season of 2017, wildfires in California and bushfires in Australia, to recent major typhoons and wondering if climate change is driving extreme weather risk, and what it could do in the future. They’re asking whether the current extent of climate change risk is priced into their premiums. Regulators are also beginning to conduct stress tests on the potential impact of climate change in the future, and insurers must respond. How will climate change impact how the market operates? Similar to any risk, insurers need to understand and quantify how the physical risk of climate change will impact their portfolios and adjust their strategy accordingly. Also, over the coming years it appears likely that regulators will incorporate climate change reporting into their regimes. Once an insurer understands their exposure to climate change risk, they can then start to take action — which will impact how the market operates. These actions could be in the form of premium changes, mitigating actions such as supporting physical defenses, diversifying the risk or taking on more capital. How is RMS responding to market needs around climate change? RMS is listening to the needs of clients to understand their pain points around climate change risk, what actions they are taking and how we can add value. We’re working with a number of clients on bespoke studies that modify the current view of risk to project into the future and/or test the sensitivity of current modeling assumptions. We’re also working to help clients understand the extent to which climate change is already built into risk models, to educate clients on emerging climate change science and to explain whether there is or isn’t a clear climate change signal for a particular peril. Cyber: Dr. Christos Mitas, Vice President, Model Development How is this change currently manifesting itself? While cyber risk itself is not new, for anyone involved in protecting or insuring organizations against cyberattacks, they will know that the nature of cyber risk is forever evolving. This could involve changes in those perpetrating the attacks, from lone wolf criminals to state-backed actors or the type of target from an unpatched personal computer to a power-plant control system. If you take the current COVID-19 pandemic, this has seen cybercriminals look to take advantage of millions of employees working from home or vulnerable business IT infrastructure. Change to the threat landscape is a constant for cyber risk. Why is cyber risk so important and relevant right now? Simply because new cyber risks emerge, and insurers who are active in this area need to ensure they are ahead of the curve in terms of awareness and have the tools and knowledge to manage new risks. There have been systemic ransomware attacks over the last few years, and criminals continue to look for potential weaknesses in networked systems, third-party software, supply chains — all requiring constant vigilance. It’s this continual threat of a systemic attack that requires insurers to use effective tools based on cutting-edge science, to capture the latest threats and identify potential risk aggregation. How is RMS responding to market needs around cyber risk? With our latest RMS Cyber Solutions, which is version 4.0, we’ve worked closely with clients and the market to really understand the pain points within their businesses, with a wealth of new data assets and modeling approaches. One area is the ability to know the potential cyber risk of the type of business you are looking to insure. In version 4.0, we have a database of over 13 million businesses that can help enrich the information you have about your portfolio and prospective clients, which then leads to more prudent and effective risk modeling. A Time to Change Our industry is undergoing a period of significant disruption on multiple fronts. From the rapidly evolving exposure landscape and the extraordinary changes brought about by the pandemic to step-change advances in technology and seismic shifts in data analytics capabilities, the market is undergoing an unparalleled transition period. As Exceedance 2020 demonstrated, this is no longer a time for business as usual. This is what defines leaders and culls the rest. This changes everything.
As COVID-19 has spread across the world and billions of people are on lockdown, EXPOSURE looks at how the latest scientific data can help insurers better model pandemic risk The coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. In a matter of months, it has expanded from the first reported cases in the city of Wuhan in Hubei province, China, to confirmed cases in over 200 countries around the globe. At the time of writing, approximately one-third of the world’s population is in some form of lockdown, with movement and activities restricted in an effort to slow the disease’s spread. The transmissibility of COVID-19 is truly global, with even the extreme remoteness of location proving no barrier to its relentless progression as it reaches far-flung locations such as Papua New Guinea and Timor-Leste. After declaring the event a global pandemic, Dr. Tedros Adhanom Ghebreyesus, WHO director general, said: “We have never before seen a pandemic sparked by a coronavirus. This is the first pandemic caused by a coronavirus. And we have never before seen a pandemic that can be controlled. … This is not just a public health crisis, it is a crisis that will touch every sector — so every sector and every individual must be involved in the fight.” Ignoring the Near Misses COVID-19 has been described as the biggest global catastrophe since World War II. Its impact on every part of our lives, from the mundane to the complex, will be profound, and its ramifications will be far-reaching and enduring. On multiple levels, the coronavirus has caught the world off guard. So rapidly has it spread that initial response strategies, designed to slow its progress, were quickly reevaluated and more restrictive measures have been required to stem the tide. Yet, some are asking why many nations have been so flat-footed in their response. To find a comparable pandemic event, it is necessary to look back over 100 years to the 1918 flu pandemic, also referred to as Spanish flu. While this is a considerable time gap, the interim period has witnessed multiple near misses that should have ensured countries remained primed for a potential pandemic. “For very good reasons, people are categorizing COVID-19 as a game-changer. However, SARS in 2003 should have been a game-changer, MERS in 2012 should have been a game-changer, Ebola in 2014 should have been a game-changer. If you look back over the last decade alone, we have seen multiple near misses.” Dr. Gordon Woo RMS However, as Dr. Gordon Woo, catastrophist at RMS, explains, such events have gone largely ignored. “For very good reasons, people are categorizing COVID-19 as a game-changer. However, SARS in 2003 should have been a game-changer, MERS in 2012 should have been a game-changer, Ebola in 2014 should have been a game-changer. If you look back over the last decade alone, we have seen multiple near misses. “If you examine MERS, this had a mortality rate of approximately 30 percent — much greater than COVID-19 — yet fortunately it was not a highly transmissible virus. However, in South Korea a mutation saw its transmissibility rate surge to four chains of infection, which is why it had such a considerable impact on the country.” While COVID-19 is caused by a novel virus and there is no preexisting immunity within the population, its genetic makeup shares 80 percent of the coronavirus genes that sparked the 2003 SARS outbreak. In fact, the virus is officially titled “severe acute respiratory syndrome coronavirus 2,” or “SARS-CoV-2.” However, the WHO refers to it by the name of the disease it causes, COVID-19, as calling it SARS could have “unintended consequences in terms of creating unnecessary fear for some populations, especially in Asia which was worst affected by the SARS outbreak in 2003.” “Unfortunately, people do not respond to near misses,” Woo adds, “they only respond to events. And perhaps that is why we are where we are with this pandemic. The current event is well within the bounds of catastrophe modeling, or potentially a lot worse if the fatality ratio was in line with that of the SARS outbreak. “When it comes to infectious diseases, we must learn from history. So, if we take SARS, rather than describing it as a unique event, we need to consider all the possible variants that could occur to ensure we are better able to forecast the type of event we are experiencing now.” Within Model Parameters A COVID-19-type event scenario is well within risk model parameters. The RMS® Infectious Diseases Model within its LifeRisks®platform incorporates a range of possible source infections, which includes coronavirus, and the company has been applying model analytics to forecast the potential development tracks of the current outbreak. Launched in 2007, the Infectious Diseases Model was developed in response to the H5N1 virus. This pathogen exhibited a mortality rate of approximately 60 percent, triggering alarm bells across the life insurance sector and sparking demand for a means of modeling its potential portfolio impact. The model was designed to produce outputs specific to mortality and morbidity losses resulting from a major outbreak. In 2006, H5N1 exhibited a mortality rate of approximately 60 percent, triggering alarm bells across the life insurance sector and sparking demand for a means of modeling its potential portfolio impact The probabilistic model is built on two critical pillars. The first is modeling that accurately reflects both the science of infectious disease and the fundamental principles of epidemiology. The second is a software platform that allows firms to address questions based on their exposure and experience data. “It uses pathogen characteristics that include transmissibility and virulence to compartmentalize a pathological epidemiological model and estimate an abated mortality and morbidity rate for the outbreak,” explains Dr. Brice Jabo, medical epidemiologist at RMS. “The next stage is to apply factors including demographics, vaccines and pharmaceutical and non-pharmaceutical interventions to the estimated rate. And finally, we adjust the results to reflect the specific differences in the overall health of the portfolio or the country to generate an accurate estimate of the potential morbidity and mortality losses.” The model currently spans 59 countries, allowing for differences in government strategy, health care systems, vaccine treatment, demographics and population health to be applied to each territory when estimating pandemic morbidity and mortality losses. Breaking Down the Virus In the case of COVID-19, transmissibility — the average number of infections that result from an initial case — has been a critical model parameter. The virus has a relatively high level of transmissibility, with data showing that the average infection rate is in the region of 1.5-3.5 per initial infection. However, while there is general consensus on this figure, establishing an estimate for the virus severity or virulence is more challenging, as Jabo explains: “Understanding the virulence of the disease enables you to assess the potential burden placed on the health care system. In the model, we therefore track the proportion of mild, severe, critical and fatal cases to establish whether the system will be able to cope with the outbreak. However, the challenge factor is that this figure is very dependent on the number of tests that are carried out in the particular country, as well as the eligibility criteria applied to conducting the tests.” An effective way of generating more concrete numbers is to have a closed system, where everyone in a particular environment has a similar chance of contracting the disease and all individuals are tested. In the case of COVID-19 these closed systems have come in the form of cruise ships. In these contained environments, it has been possible to test all parties and track the infection and fatality rates accurately. Another parameter tracked in the model is non-pharmaceutical intervention — those measures introduced in the absence of a vaccine to slow the progression of the disease and prevent health care systems from being overwhelmed. Suppression strategies are currently the most effective form of defense in the case of COVID-19. They are likely to be in place in many countries for a number of months as work continues on a vaccine. “This is an example of a risk that is hugely dependent on government policy for how it develops,” says Woo. “In the case of China, we have seen how the stringent policies they introduced have worked to contain the first wave, as well as the actions taken in South Korea. There has been concerted effort across many parts of Southeast Asia, a region prone to infectious diseases, to carry out extensive testing, chase contacts and implement quarantine procedures, and these have so far proved successful in reducing the spread. The focus is now on other parts of the world such as Europe and the Americas as they implement measures to tackle the outbreak.” The Infectious Diseases Model’s vaccine and pharmaceutical modifiers reflect improvements in vaccine production capacity, manufacturing techniques and the potential impact of antibacterial resistance. While an effective treatment is, at time of writing, still in development, this does allow users to conduct “what-if” scenarios. “Model users can apply vaccine-related assumptions that they feel comfortable with,” Jabo says. “For example, they can predict potential losses based on a vaccine being available within two months that has an 80 percent effectiveness rate, or an antiviral treatment available in one month with a 60 percent rate.” Data Upgrades Various pathogens have different mortality and morbidity distributions. In the case of COVID-19, evidence to date suggests that the highest levels of mortality from the virus occur in the 60-plus age range, with fatality levels declining significantly below this point. However, recent advances in data relating to immunity levels has greatly increased our understanding of the specific age range exposed to a particular virus. “Recent scientific findings from data arising from two major flu viruses, H5N1 and A/H7N9, have had a significant impact on our understanding of vulnerability,” explains Woo. “The studies have revealed that the primary age range of vulnerability to a flu virus is dependent upon the first flu that you were exposed to as a child. “There are two major flu groups to which everyone would have had some level of exposure at some stage in their childhood. That exposure would depend on which flu virus was dominant at the time they were born, influencing their level of immunity and which type of virus they are more susceptible to in the future. This is critical information in understanding virus spread and we have adapted the age profile vulnerability component of our model to reflect this.” Recent model upgrades have also allowed for the application of detailed information on population health, as Jabo explains: “Preexisting conditions can increase the risk of infection and death, as COVID-19 is demonstrating. Our model includes a parameter that accounts for the underlying health of the population at the country, state or portfolio level. “The information to date shows that people with co-morbidities such as hypertension, diabetes and cardiovascular disease are at a higher risk of death from COVID-19. It is possible, based on this data, to apply the distribution of these co-morbidities to a particular geography or portfolio, adjusting the outputs based on where our data shows high levels of these conditions.” Predictive Analytics The RMS Infectious Diseases Model is designed to estimate pandemic loss for a 12-month period. However, to enable users to assess the potential impact of the current pandemic in real time, RMS has developed a hybrid version that combines the model pandemic scenarios with the number of cases reported. “Using the daily cases numbers issued by each country,” says Jabo, “we project forward from that data, while simultaneously projecting backward from the RMS scenarios. Using this hybrid approach, it allows us to provide a time-dependent estimate for COVID-19. In effect, we are creating a holistic alignment of observed data coupled with RMS data to provide our clients with a way to understand how the evolution of the pandemic is progressing in real time.” Aligning the observed data with the model parameters makes the selection of proper model scenarios more plausible. The forward and backward projections, as illustrated, not only allow for short-term projections, but also forms part of model validation and enables users to derive predictive analytics to support their portfolio analysis. “Staying up to date with this dynamic event is vital,” Jabo concludes, “because the impact of the myriad government policies and measures in place will result in different potential scenarios, and that is exactly what we are seeing happening.”